GBIO vs. ELDN, CCCC, THTX, PEPG, MOLN, NKTX, ANRO, NVCT, CRDF, and ACOG
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Eledon Pharmaceuticals (ELDN), C4 Therapeutics (CCCC), Theratechnologies (THTX), PepGen (PEPG), Molecular Partners (MOLN), Nkarta (NKTX), Alto Neuroscience (ANRO), Nuvectis Pharma (NVCT), Cardiff Oncology (CRDF), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.
Generation Bio vs. Its Competitors
Generation Bio (NASDAQ:GBIO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.
Eledon Pharmaceuticals has lower revenue, but higher earnings than Generation Bio. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Generation Bio has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.
In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Generation Bio. MarketBeat recorded 2 mentions for Eledon Pharmaceuticals and 0 mentions for Generation Bio. Generation Bio's average media sentiment score of 0.00 beat Eledon Pharmaceuticals' score of -0.36 indicating that Generation Bio is being referred to more favorably in the media.
95.2% of Generation Bio shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 21.8% of Generation Bio shares are owned by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Generation Bio's net margin of -341.12%. Generation Bio's return on equity of -91.07% beat Eledon Pharmaceuticals' return on equity.
Generation Bio currently has a consensus target price of $10.67, indicating a potential upside of 73.87%. Eledon Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 189.44%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Generation Bio.
Summary
Generation Bio beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GBIO) was last updated on 10/22/2025 by MarketBeat.com Staff
